{"disease":{"id":"lower-respiratory-tract-disease","name":"lower respiratory tract disease"},"drugs":{"marketed":[{"drug_id":"nirsevimab","indication_name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Beyfortus","generic_name":"NIRSEVIMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"RSV","drug_class":"Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]","quality_score":10,"revenue":"800","mechanism":"BEYFORTUS is a monoclonal antibody that targets RSV."},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain chronic lung conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain heart conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"beyfortus","indication_name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Beyfortus","company_name":"National Institute of Allergy and Infectious Diseases (NIAID)","drug_phase":"marketed","molecular_target":"Fusion glycoprotein F0","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"rsvpref-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV-associated hospitalization due to prematurity.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF Vaccine","generic_name":"rsvpref-vaccine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"RSV","drug_class":"vaccine","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"rsvpref-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in young children with a history of premature birth or bronchopulmonary dysplasia.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF Vaccine","generic_name":"rsvpref-vaccine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"RSV","drug_class":"vaccine","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"rsvpref-mdv","indication_name":"Prevention of RSV lower respiratory tract disease in neonates at high risk of RSV disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF MDV","generic_name":"rsvpref-mdv","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"RSV F protein","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"rsvpref-mdv","indication_name":"Prevention of RSV lower respiratory tract disease in infants and children at high risk of RSV disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF MDV","generic_name":"rsvpref-mdv","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"RSV F protein","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"nirsevimab-alip","indication_name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BEYFORTUS","generic_name":"NIRSEVIMAB-ALIP","company_name":"ASTRAZENECA AB","drug_phase":"marketed","molecular_target":"Fusion glycoprotein F0","drug_class":"Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"rsvpref","indication_name":"Prevention of RSV lower respiratory tract disease in neonates at high risk of RSV disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF","generic_name":"rsvpref","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"RSV F protein","drug_class":"Monoclonal antibody","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"rsvpref","indication_name":"Prevention of RSV lower respiratory tract disease in infants and children at high risk of RSV disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF","generic_name":"rsvpref","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"RSV F protein","drug_class":"Monoclonal antibody","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"rsvpref-120-g","indication_name":"Prevention of RSV lower respiratory tract disease in neonates at high risk of RSV disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF 120 µg","generic_name":"rsvpref-120-g","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Prefusion form of the RSV F protein","drug_class":"Recombinant subunit vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to prematurity.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"rsvpref-120-g","indication_name":"Prevention of RSV lower respiratory tract disease in infants and children at high risk of RSV disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF 120 µg","generic_name":"rsvpref-120-g","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Prefusion form of the RSV F protein","drug_class":"Recombinant subunit vaccine","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":14,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07416266","title":"Lower Respiratory Tract Infections Managed in Primary Care in France","phase":"","overall_status":"COMPLETED","enrollment_count":230066,"lead_sponsor_name":"Hôpital Raymond Poincaré","has_results":false},{"nct_id":"NCT04908683","title":"A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":25236,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT07445763","title":"TARSILA Real-World Evidence Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Inova Medical","has_results":false},{"nct_id":"NCT03392363","title":"Diagnosing Respiratory Disease in Children Using Cough Sounds 2","phase":"","overall_status":"COMPLETED","enrollment_count":1470,"lead_sponsor_name":"ResApp Health Limited","has_results":false},{"nct_id":"NCT03011515","title":"Evaluating a Host-response Based Diagnostic for Distinguishing Between Bacterial and Viral Etiology in Patients With Lower Respiratory Tract Infection (LRTI)","phase":"","overall_status":"COMPLETED","enrollment_count":583,"lead_sponsor_name":"MeMed Diagnostics Ltd.","has_results":false},{"nct_id":"NCT07295028","title":"Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Vicebio Australia Proprietary Limited","has_results":false},{"nct_id":"NCT05327816","title":"A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":132,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT06924528","title":"The Effects Of Toy In Chıldren Durıng Inhaler Therapy","phase":"NA","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Bakirkoy Dr. Sadi Konuk Research and Training Hospital","has_results":false},{"nct_id":"NCT06149494","title":"RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Altesa Biosciences, Inc.","has_results":false},{"nct_id":"NCT07122661","title":"STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1,"lead_sponsor_name":"Pfizer","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}